PRESS RELEASE

Unither Pharmaceuticals to highlight development capabilities and drug delivery innovation at BioFIT 2026

The company will present its small-batch and sterile development capabilities in Bordeaux and showcase Euroject®, its BFS-based single-dose injectable device.

PARIS, FRANCE, NOVEMBER 2026 – Unither Pharmaceuticals, a global CDMO specialising in liquid dosage forms, will participate in the 15th edition of BioFIT, taking place on December 10 and 11, 2026, in Marseille, France.

At BioFIT 2026, Unither will highlight its capabilities for supporting pharmaceutical and biotech companies from early development through clinical manufacturing and small commercial batches. The company will also showcase Euroject®, its innovative Blow-Fill-Seal (BFS)-based single-dose injectable device.

From early development to small-batch manufacturing

Unither's Bordeaux Development centre supports projects through formulation and analytical development, regulatory support and small-scale manufacturing. Its capabilities cover preclinical and clinical batches, pilot and technical batches, and small commercial volumes, making the site particularly relevant for projects that do not initially require large-scale production.

The centre supports projects including ophthalmic products, orphan drugs, rare diseases, repositioned molecules and targeted therapies. Its integrated approach is designed to facilitate the transition from pharmaceutical development to clinical supply, first commercial batches and subsequent industrial transfer.

For sterile ophthalmic projects, the Bordeaux centre has strengthened its capabilities with a GMP pilot area and a sterile isolator designed to support preclinical, clinical and small commercial batches. Standard multidose (preserved) and preservative-free multidose projects can begin with batch sizes of up to 10 litres for early preclinical and clinical phases before subsequent industrial scale-up within Unither's manufacturing network.

Showcasing Euroject® for vaccines and biologics

BioFIT will also provide an opportunity for Unither to showcase Euroject®, its BFS-based prefilled single-dose injectable device developed for vaccines and biologics.

Building on Unither's BFS expertise, Euroject® combines a ready-to-use single-dose format with an automated aseptic manufacturing process. The platform is designed to

support simplified preparation, scalable manufacturing and a robust supply approach for injectable products.

The presentation comes alongside new scientific data on the performance of Euroject® under demanding cold-chain conditions. In a recent article published in ONdrugDelivery, Unither experts Pauline Genovese, Alexandre Fontayne and Laury Livemont present findings from nine studies investigating the effects of freeze-thaw cycles on the system, including freezing conditions down to -80°C. Across the conditions tested, the studies showed no leakage and dose-delivery efficiencies above 98%, while analyses indicated preservation of the LDPE material's thermal, mechanical and viscoelastic properties. These findings provide additional data on Euroject® performance for injectable products requiring stringent cold-chain management.

Meet Unither at BioFIT 2026

Through its pharmaceutical development capabilities and drug delivery innovations such as Euroject®, Unither will engage with biotech companies and innovation partners looking for solutions to advance projects from development towards industrialisation.

Event	BioFIT 2026
Dates	December 10-11, 2026
Location	Parc Chanot, Palais de l'Europe, Marseille, France
Booth	D13

About Unither Pharmaceuticals

Unither Pharmaceuticals is a global contract development and manufacturing organisation specialising in liquid dosage forms. The company supports pharmaceutical and biotech partners in the development and manufacture of products using technologies including Blow-Fill-Seal, standard multidose (preserved), preservative-free multidose, liquid stick packs and other innovative drug delivery solutions.

Media contact

Unither Pharmaceuticals
press@unither-pharma.com
www.unither-pharma.com